[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-neoplasm-of-breast\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-neoplasm-of-breast":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,59,84,117,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100054018","collection-of-csf-samples-from-participants-with-metastatic-triple-negative-breast-cancer-tnbc-and-her2-breast-cancer-with-no-prior-history-nor-active-radiographically-detectable-brain-metastases-100054018",false,"NCT07619534","Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases","Sample Collection Study to Analyze Cerebral Spinal Fluid as a Biomarker for Brain Metastasis in Metastatic Breast Cancer","* INCLUSION CRITERIA:\n* Pathology documentation of histologically confirmed HER2+ BC or TNBC with a history of metastatic disease.\n* Participants must be able to undergo lumbar puncture (LP) and brain MRI.\n* Women age \\>= 18 years\n* Adequate organ function as defined below:\n\n  * Creatinine \\\u003C=1.5 x institutional upper limit of normal (ULN)\n\nOR\n\n--Calculated Creatinine clearance \\>=40 mL\u002Fmin\u002F1.73 m2 for individuals with creatinine levels above institutional ULN (using either Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] equation)\n\n\\- Participants must be able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Prior history or current MRI-detected brain metastasis or leptomeningeal disease\n* Previous history of any invasive malignancies, except for surgically resected local cutaneous malignancies.\n* Pregnancy","ALL","18 Years","120 Years",{"count":20,"type":21},139,"ESTIMATED","OBSERVATIONAL","Background:\n\nBreast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or brain. Breast cancer that spreads to the brain is often fatal. Researchers want to know if tumor DNA found in spinal fluid, blood, or tumor tissue can help predict when the cancer will spread to the brain. They want to collect these fluid and tissue samples for research.\n\nObjective:\n\nTo collect spinal fluid and other samples from people with breast cancer that has spread to other parts of the body.\n\nEligibility:\n\nPeople aged 18 years and older with HER2-positive or triple negative breast cancer. The cancer must have spread to other parts of the body but not to the brain.\n\nDesign:\n\nParticipants will be screened. They will have blood tests to assess kidney function. They will have an imaging scan of the brain.\n\nParticipants will come to the NIH clinic to have their samples collected:\n\n* Spinal fluid. A thin needle will be inserted into the lower back to draw out a sample of fluid from the space around the spinal cord. A physical exam and blood tests will be done to make sure it is safe for participants to have this procedure.\n* Blood.\n* Saliva or cheek swabs. They will rub a cotton swab inside of their mouth.\n* Tumor samples. If participants have had samples of tumor tissue (biopsies) collected in the past, leftover tissue may be used for this study.\n\nParticipants will be contacted for follow-up every 6 months for 3 years. They may return once a year to provide further samples....",[25,26,27,28],"Breast Cancer","Breast Carcinoma","Cancer of the Breast","Malignant Neoplasm of Breast",[30,31,32,33],"Triple Negative Breast Cancer (TNBC)","HER2-Postitive","Metastatic Breast Cancer","Cerebral Spinal Fluid Collection","NOT_YET_RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":21},"2026-07-16",{"date":42,"type":21},"2034-07-01",{"name":44,"class":45},"National Cancer Institute (NCI)","NIH",1,{"id":48,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":50,"keywords":51,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":46},"100638410",{"count":20,"type":21},[25,26,27,28],[30,31,32,33],"2026-07-01",{"date":54,"type":38},"2026-07-02",{"date":56,"type":21},"2026-07-07",{"date":42,"type":21},{"name":44,"class":45},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":46},"100412719","swedish-ibrance-registries-insights-siri-100412719","NCT04654208","Swedish Ibrance Registries Insights (SIRI)","Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)","SIRI","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)\n2. Age ≥18 years at index date\n\nExclusion Criteria:\n\nThere are no exclusion criteria",{"count":68,"type":21},1500,"The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.",[28],[72],"metastatic breast cancer (MBC)","RECRUITING","2026-03-29",{"date":76,"type":38},"2026-03-31",{"date":78,"type":38},"2020-12-15",{"date":80,"type":21},"2026-05-31",{"name":82,"class":83},"Pfizer","INDUSTRY",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":105,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100535416","phase-1-trail-r2-and-her2-bi-specific-chimeric-antigen-receptor-car-t-cells-for-the-treatment-of-metastatic-breast-cancer-100535416","NCT06251544","TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer","(TRAILBLASER) TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor T Cells for the Treatment of Metastatic Breast Cancer","Procurement Inclusion Criteria:\n\n1. Any patient between 18-80 years of age regardless of sex, with a diagnosis of metastatic or locally recurrent unresectable HER2 positive breast cancer.\n2. HER2 tumor expression1+, 2+ or 3+ by IHC\n3. The disease must have progressed after standard first line therapy. Patients are still eligible if they have failed more than one line of therapy.\n4. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\nTreatment Inclusion Criteria:\n\n1. Patients between ages 18 and 80 years old with a diagnosis of either stage IV breast cancer or locally recurrent unresectable breast cancer. Disease must have progressed after standard first line therapy. Patients are still eligible if they have failed more than one line of therapy.\n2. Measurable or evaluable disease per RECIST 1.1 criteria.\n3. HER2 tumor expression 1+, 2+ or 3+ by IHC.\n4. Bilirubin ≤ 3x upper limit of normal.\n5. AST and ALT ≤ 3x upper limit of normal\n6. Hemoglobin ≥ 7 g\u002Fdl (may be transfused values)\n7. Serum creatinine \\\u003C 2 x the upper limit of normal.\n8. Pulse oximetry of \\> 90% on room air.\n9. Off conventional or investigational therapy for 3 weeks prior to study entry.\n10. ECOG Performance Status ≤ 2\n11. The patient is able to understand and give informed consent to study related procedures and treatments.\n\nProcurement Exclusion Criteria:\n\n1. Known pregnancy or actively breast feeding.\n2. Active and uncontrolled bacterial, viral, or fungal infection.\n3. Patients with current use of systemic corticosteroids (Prednisone equivalent \\>0.5mg\u002Fkg\u002Fday).\n4. Patients with abnormal left ventricular function (LVEF \\\u003C55%)\n5. Patients with brain metastases that are progressing.\n\nTreatment Exclusion Criteria:\n\n1. Pregnant or breast feeding\n2. Active and uncontrolled bacterial, viral or fungal infection\n3. Patient with current use of systemic corticosteroids (prednisone equivalent \\>0.5 mg\u002Fkg\u002Fday.\n4. Patients with abnormal left ventricular function (LVEF \\\u003C55%).\n5. Patients with brain metastases that are progressing","80 Years",{"count":93,"type":21},27,"INTERVENTIONAL",[96],"PHASE1","The purpose of this study is to find the biggest dose of HTR2 T cells that is safe, to see how long these cells last in the body, to learn the side effects, and to see if these cells are able to fight and kill HER2 expressing breast cancer.\n\nPatients eligible for this study have metastatic breast cancer that has HER2 expression and has progressed on at least one line of therapy. This is a gene transfer research study using special immune cells called T cells. T cells are a type of white blood cell that helps the body recognize and fight cancer cells.\n\nThe body has different ways of fighting diseases and no single way seems perfect for fighting cancer. This research combines two different ways of fighting cancer: antibodies and T cells. Antibodies are proteins that protect the body from infectious disease and possibly cancer. T cells, or T lymphocytes, are special blood cells that can kill other cells, including tumor cells. Both antibodies and T cells have shown promise treating cancer but have not been strong enough to cure most patients.\n\nPrevious research has found that investigators can put genes into T cells that helps them recognize cancer cells and kill them. Investigators now want to see if by putting a new gene in those T cells to help recognize breast cancer cells expressing HER2 can kill the cancer cells. In clinical trials for various cancer types that express HER2, our center engineered a CAR that recognizes HER2 and put this CAR into patients own T cells and gave them back. Investigators saw that the cells did grow and patients did tolerate and respond to the treatment.\n\nInvestigators will add a gene to the HER2 recognizing CAR T cells that will improve the T cells function. Investigators know that some immune cells in the body can lower T cells ability to kill cancer cells. Investigators have identified an antibody that will inactivate those immune suppressive cells thereby allowing T cells to survive better to recognize and kill cancer cells. This antibody targets the Trail-R2 receptor and is referred to as TR2.\n\nAlso, investigators know that T cells need the support of cytokines to perform their immune functions. There is evidence showing that the addition of interleukin 15 (IL15) enhances CAR T cells ability to kill cancer cells. As a result, investigators also added IL15 to the HER2 and TR2 targeting CAR T cells (HTR2 T cells).\n\nThe HTR2 T cells are an investigational product not approved by the Food and Drug Administration.",[25,99,100,28,101,102,103,104],"Tumor, Breast","Breast Tumor","Mammary Cancer","Mammary Neoplasm","Mammary Neoplasms, Human","Neoplasm, Breast",[106],"HER2 positive","2026-03-02",{"date":109,"type":38},"2026-03-04",{"date":111,"type":21},"2026-06",{"date":113,"type":21},"2044-01",{"name":115,"class":116},"Baylor College of Medicine","OTHER",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":124,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":94,"phases":127,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100321368","confirmatory-clinical-evaluation-of-novilase-laser-therapy-for-focal-destruction-of-malignant-breast-tumors-100321368","NCT03463954","Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors","Prospective, Multicenter Confirmatory Clinical Evaluation of Novilase® Interstitial Laser Therapy for the Focal Destruction of Malignant Breast Tumors ≤15 mm (BR-003)","Inclusion Criteria:\n\n* Females, aged 18 years and older\n* Able to give written informed consent herself\n* Definitive pathologic diagnosis by needle core biopsy\n* Unifocal malignant tumor (T1a-c, N0-1, M0) that does not exceed 15 mm in longest dimension and measures at least 5 mm away from the skin and chest wall, or can be moved at least 5 mm away from the skin and chest wall by injection of saline or local anesthetic\n* No more than 10 mm of calcifications confined to the tumor on imaging\n* Tumor is well visualized through ultrasound or x-ray mammography imaging and amenable to image-guidance therapy (i.e., a tumor which is well visualized through imaging can be identified from surrounding breast tissue and does not have margins obscured by other structures or artifacts on the images)\n* Tumor is well visualized on MRI\n* Subject with mammographic appearance of overall dense parenchymal tissue may be included, as long as a clearly evident marker is present at tumor site\n* Tumor with less than 25% intraductal component, as determined by core biopsy\n* No clinically significant co-morbidities (e.g., chronic illnesses existing simultaneously with and usually independent of breast cancer) that affect life expectancy\n* Subject weight limited to ≤300 lbs. or ≤136 kg\n* Subject agrees to comply with standard of care radiation or adjuvant therapy as prescribed by physician\n\nExclusion Criteria:\n\n* Subject younger than 18 years of age\n* Pregnant or breast-feeding\n* Tumor poorly visualized by ultrasound or x-ray mammography imaging\n* Contraindications to administration of gadolinium-based contrast agent, including: prior allergic reaction to a gadolinium-based contrast agent, moderate to end-stage kidney disease, and\u002For acute or chronic severe renal insufficiency (Glomerular filtration rate (GFR) \\\u003C30ml\u002Fmin\u002F1.73 sq. meters)\n* Contraindications to MRI according to site guidelines (e.g., cardiac pacemaker, metallic implants)\n* History of severe asthma\n* Tumor measuring greater than 15 mm in longest dimension\n* Microcalcifications that extend beyond target tumor such that overall longest dimension of target tumor and calcifications is longer than 15 mm.\n* Advanced stage breast cancer\n* Tumors that are lobular neoplasm, metastatic carcinoma to breast, sarcoma, Phyllodes tumor, or Paget's disease\n* Tumor with only DCIS with microinvasion\n* Extensive intraductal component in lesion (i.e., \\>25%) as determined by core biopsy\n* Subject who is known to be BRCA positive\n* Tumor that is ER\u002FPR\u002FHER2 negative (TNBC)\n* Inability to lie in prone or supine position for one hour\n* Subject who is currently participating in another investigational treatment, device or drug study through follow up that would interfere with this trial\n* Subject without a definitive HER2 test according to ASCO\u002FCAP guidelines","FEMALE",{"count":126,"type":21},122,[128],"NA","Prior to this confirmatory pivotal study, the multicenter Br-002 feasibility study was completed. 98% of tumors less than or equal to 15mm were completely ablated in one procedure.This study will evaluate Novilase for the focal destruction of malignant tumors of the breast that are less than or equal to 15 mm against a performance goal for the standard of care, lumpectomy. The ASBrS' goal of less than 20% retreatment by 2020 was selected as a representative performance goal, i.e., 80.0%, and is consistent with published effectiveness rates for lumpectomy.",[28],[132],"less than or equal to 15 mm","2026-02-17",{"date":135,"type":38},"2026-02-19",{"date":137,"type":38},"2023-08-09",{"date":139,"type":21},"2027-03-30",{"name":141,"class":83},"Novian Health Inc.",13,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":124,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":94,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":168,"locationsCount":46},"100413921","accelerated-partial-breast-irradiation-versus-standard-or-hypofractionated-whole-breast-irradiation-in-early-breast-cancer-after-breast-conserving-surgery-100413921","NCT04669873","Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery","Clinical Trial, Randomized, Open Label, With an Active Comparator to Assess the Efficacy and Safety of Using Accelerated Partial Irradiation Versus Standard or Hypofractionated Irradiation of the Entire Breast in Patients With Initial Breast Cancer After Conservative Surgery","LAPIDARY","Inclusion Criteria:\n\n* Information to the patient and signed informed consent;\n* Women aged ≥50 years\n* Breast conserving surgery\n* Pathologic tumor size \\\u003C 3 cm (maximum microscopic diameter of the invasive component)\n* Invasive adenocarcinoma (except classic invasive lobular carcinoma)\n* Unifocal disease\n* Histopathologic grades I or II\n* Eastern Cooperative Oncology Group (ECOG) 0-1\n* Lymphovascular invasion absent\n* Negative axillary lymph nodes\n* Minimum microscopic margins of non-cancerous tissue of 2mm (excluding deep margin when in deep fascia)\n* No prior breast or mediastinal radiotherapy\n* No hematogenous metastases\n\nExclusion Criteria:\n\n* Previous malignancy (except non-melanomatous skin cancer)\n* Mastectomy\n* Classical-Type Invasive Lobular Carcinoma\n* Neoadjuvant chemotherapy\n* Human Epidermal growth factor Receptor-type 2 positive (HER2+)\n* Triple-negative breast cancers\n* Intravascular lymphoma present\n* Contraindications to radiotherapy.\n* No geographical, social or psychologic reasons that would prevent study follow","50 Years","90 Years",{"count":154,"type":21},36,[128],"Radiotherapy has been confirmed as an important treatment breast-conserving surgery reducing the risk of any recurrence of breast cancer and breast cancer-related mortality in patients with early breast cancer.\n\nThere are no comparative data on the ideal radiotherapy treatment regimen for patients with early stage breast cancer who underwent conservative surgery in the Brazilian population.",[28],[25,159,160,161],"Radiotherapy","Hypofractionated","Breast-conserving surgery","2021-03-04",{"date":164,"type":38},"2021-03-08",{"date":162,"type":38},{"date":167,"type":21},"2026-12-31",{"name":169,"class":116},"Instituto Brasileiro de Controle do Cancer"]